Aktienanalyse zu Dyadic International Inc (DYAI)DYAIDyadic International Inc

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Dyadic International Inc is not a good buy right now due to its current price of 0.3398, which is very close to its 52-week low of 0.33, and an RSI of 26.108 indicating oversold conditions. The company has also reported a significant year-to-date change of -63.85%, reflecting ongoing financial struggles. The main risk is the negative trend in net income, which has been consistently negative, with the latest reported net income of -2,123,884 USD in Q2 2026.